Figure 3. [Based on linear measurements, relative...]. - Endotext

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Endotext [Internet].

Show details

Figure 3.

Based on linear measurements, relative wall thickness and left ventricular mass index determine left ventricular geometric patterns. LVH, left ventricular hypertrophy.

From: Diabetes, Cardiomyopathy, and Heart Failure

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Contents

Views

Cite this Page
Oktay AA, Paul TK, Koch CA, et al. Diabetes, Cardiomyopathy, and Heart Failure. [Updated 2023 Sep 26]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Figure 3. [Based on linear measurements, relative...].

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Similar articles in PubMed

Review Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.[Circulation. 2017]
Review Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Circulation. 2017 Oct 24; 136(17):1643-1658.
Review Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.[Cardiovasc Hematol Agents Med ...]
Review Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.
Gitto M, Vrachatis DA, Condorelli G, Papathanasiou K, Reimers B, Deftereos S, Stefanini GG. Cardiovasc Hematol Agents Med Chem. 2022; 20(2):90-102.
Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.[Glob Cardiol Sci Pract. 2023]
Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
Kotit S. Glob Cardiol Sci Pract. 2023 May 11; 2023(2):e202314. Epub 2023 May 11.
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.[Int J Mol Sci. 2021]
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
Lymperopoulos A, Borges JI, Cora N, Sizova A. Int J Mol Sci. 2021 Jul 19; 22(14). Epub 2021 Jul 19.
Review Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.[Front Cardiovasc Med. 2021]
Review Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Zeng Q, Zhou Q, Liu W, Wang Y, Xu X, Xu D. Front Cardiovasc Med. 2021; 8:636152. Epub 2021 Feb 10.

See reviews...See all...

Recent Activity

Clear Turn Off Turn On

Figure 3. [Based on linear measurements, relative...]. - Endotext
Figure 3. [Based on linear measurements, relative...]. - Endotext
Homo sapiens chromosome 1 open reading frame 54 (C1orf54), mRNA
Homo sapiens chromosome 1 open reading frame 54 (C1orf54), mRNA
gi|142350824|ref|NM_024579.2|
Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on